These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33670479)

  • 1. Recurrent Mutations in
    Łukomska A; Menkiszak J; Gronwald J; Tomiczek-Szwiec J; Szwiec M; Jasiówka M; Blecharz P; Kluz T; Stawicka-Niełacna M; Mądry R; Białkowska K; Prajzendanc K; Kluźniak W; Cybulski C; Dębniak T; Huzarski T; Tołoczko-Grabarek A; Byrski T; Baszuk P; Narod SA; Lubiński J; Jakubowska A
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor.
    Ogrodniczak A; Menkiszak J; Gronwald J; Tomiczek-Szwiec J; Szwiec M; Cybulski C; Dębniak T; Huzarski T; Tołoczko-Grabarek A; Byrski T; Białkowska K; Prajzendanc K; Baszuk P; Lubiński J; Jakubowska A
    Hered Cancer Clin Pract; 2022 Mar; 20(1):11. PubMed ID: 35313928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.
    Wojcik P; Jasiowka M; Strycharz E; Sobol M; Hodorowicz-Zaniewska D; Skotnicki P; Byrski T; Blecharz P; Marczyk E; Cedrych I; Jakubowicz J; Lubiński J; Sopik V; Narod S; Pierzchalski P
    Hered Cancer Clin Pract; 2016; 14():5. PubMed ID: 26843898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to male breast cancer in Poland.
    Szwiec M; Tomiczek-Szwiec J; Kluźniak W; Wokołorczyk D; Osowiecka K; Sibilski R; Wachowiak M; Gronwald J; Gronwald H; Lubiński J; Cybulski C; Narod SA; Huzarski T
    BMC Cancer; 2021 Aug; 21(1):975. PubMed ID: 34461861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of pathogenic non-founder germline mutations in
    Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
    Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
    Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.
    Rogoża-Janiszewska E; Malińska K; Cybulski C; Jakubowska A; Gronwald J; Huzarski T; Lener M; Górski B; Kluźniak W; Rudnicka H; Akbari MR; Kashyap A; Narod SA; Lubiński J; Dębniak T; On Behalf Of The Polish Hereditary Breast Cancer Consortium
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of mutations predisposing to familial breast cancer in Poland.
    Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Rusak B; Stempa K; Gronwald J; Szymiczek A; Bagherzadeh M; Jakubowska A; Dębniak T; Lener M; Rudnicka H; Szwiec M; Jarkiewicz-Tretyn J; Stawicka M; Domagała P; Narod SA; Lubiński J; Akbari MR;
    Int J Cancer; 2019 Dec; 145(12):3311-3320. PubMed ID: 31173646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
    Ancot F; Arcand SL; Mes-Masson AM; Provencher DM; Tonin PN
    Oncol Lett; 2015 Jun; 9(6):2787-2790. PubMed ID: 26137147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
    Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
    JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
    Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
    Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland.
    Jasiewicz A; Rudnicka H; Kluźniak W; Gronwald W; Kluz T; Cybulski C; Jakubowska A; Lubiński J; Gronwald J
    Hered Cancer Clin Pract; 2022 Apr; 20(1):12. PubMed ID: 35382848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of Pathogenic Germline Variants in
    Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.